Jenna Eagles

TL;DR: The flagship paper of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium describes the generation of the integrative analyses of 2,658 whole-cancer genomes and their matching normal tissues across 38 tumour types, the structures for international data sharing and standardized analyses, and the main scientific findings from across the consortium studies.

TL;DR: Deep sequencing is used to analyse genes that are recurrently mutated in AML to distinguish between individuals who have a high risk of developing AML and those with benign ARCH, providing proof-of-concept that it is possible to discriminate ARCH from pre-AML many years before malignant transformation.

TL;DR: The potential for broad clinical utility of ctDNA-based surveillance in patients treated with ICB is demonstrated, and 12 patients with ct DNA clearance during treatment were alive with median 25 months follow up.

TL;DR: Established clinical co-variates dominated survival analyses, although CCP and hypoxia may inform clinical practice, and cell cycle progression increased with sequential inactivation of tumor suppressors, yet remained higher in metastases.